Xuzhou, China Clinical Trials

A listing of Xuzhou, China clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

acute coronary syndrome
percutaneous coronary intervention
aspirin
ticagrelor
The third people's hospital
 (6.7 away) Contact site
  • 4 views
  • 20 Jun, 2021
  • +7 other locations
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)

The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or 3 allele and ticagrelor in carriers of a CYP2C192 or *3 allele in patients treated with new generation drug eluting stents.

acute coronary syndrome
artery disease
clopidogrel
ticagrelor
percutaneous coronary intervention
Beijing Tian Tan Hospital
 (391.0 away) Contact site
  • 1 views
  • 27 Jan, 2021
  • +11 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

chemoradiotherapy
esophageal carcinoma
oxaliplatin
carcinoma
pembrolizumab
The Affiliated Hospital of Xuzhou Medical University ( Site 0522)
 (8.9 away) Contact site
  • 32 views
  • 18 Jun, 2021
  • +143 other locations
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System Metastases

Primary Hypothesis The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Central Nervous System (CNS) metastasis Secondary Hypothesis The safety profile …

brain metastases
EGFR
metastasis
tyrosine
epidermal growth factor receptor
China site 0126
 (8.9 away) Contact site
  • 53 views
  • 25 Jan, 2021
  • +58 other locations
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

This is a randomized, double-blinded, multicenter study to evaluate the efficacy and safety of HX008 injection combined with irinotecan versus placebo combined with irinotecan as second-line therapy in patients with adcanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have had tumor progression after first-line treatment with platinum and/or fluropyrimidine therapy.

adenocarcinoma
fluoropyrimidine
metastatic adenocarcinoma
irinotecan
gastric adenocarcinoma
Xuzhou Central Hospital
 (6.1 away) Contact site
  • 0 views
  • 03 Feb, 2021
  • +63 other locations
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).

durvalumab
capecitabine
fluorouracil
carcinoma
squamous cell carcinoma
Research Site
 (7.5 away) Contact site
  • 0 views
  • 01 Jun, 2021
  • +112 other locations
A Phase 2 Study to Evaluate the Efficacy and Safety of BN101 in Subject With cGVHD

This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.

The First Affiliated Hospital of Soochow University
 (276.6 away) Contact site
  • 0 views
  • 24 Jun, 2021
  • +7 other locations
A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell lung cancer (SCLC) patients without disease progression after first-line platinum containing chemotherapy, objective response rate (ORR) in SCLC patients with recurrence or progression after first-line platinum containing chemotherapy, and orr in SCLC patients with …

topotecan
gemcitabine
alopecia
neutrophil count
etoposide
General hospital of eastern theater command
 (171.5 away) Contact site
  • 0 views
  • 28 May, 2021
  • +8 other locations
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL NOS

The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1 expression in EBV+ DLBCL. The investigators therefore design this phase II study to investigate the safety and efficacy of sintilimab (an anti-PD-1 antibody) in combination with R-CHOP in patients with treatment-naive EBV+ DLBCL.

Xuzhou Central Hospital
 (6.1 away) Contact site
  • 0 views
  • 23 Jan, 2021
  • +10 other locations
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

This is a Phase II, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of RC48-ADC with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), …

immunostimulant
EGFR
epidermal growth factor receptor
locally advanced breast cancer
growth factor
Linyi Cancer Hospital
 (86.7 away) Contact site
  • 128 views
  • 15 Mar, 2021
  • +42 other locations